Skip to main content

Table 3 Total-C (mg/dL) in the 19 patients who completed the study

From: LDL-cholesterol lowering effect of a new dietary supplement: an open label, controlled, randomized, cross-over clinical trial in patients with mild-to-moderate hypercholesterolemia

  Argicolina Normolip Argicolina−Normolip
At start of treatment 221.1 ± 16.5 221.6 ± 18.0 −0.5 (−9.8  +8.8)
At end of treatment 178.3 ± 16.3* 187.0 ± 17.1* −8.7 (− 15.3  −2.1)
Δ Final–Initial −42.7 (−53.6  −31.8) −34.6 (−46.1  −23.1) −8.2 (−19.9  +3.5)
% Δ (Final–Initial) / Initial −19.0 (−23.5  −14.4) −15.2 (−19.8  −10.5) −3.8 (−8.2  +0.6)
  1. Data are expressed as mean ± SD, (95%CI), and analyzed by Student’s t test for paired data (end vs. start of treatment), * p < 0.0001